Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial

Autor:	Cyril W. C. Kendall, David J.A. Jenkins, Dorothea Faulkner, Mary Ann Ryan, Tina Parker, Edward Vidgen, Vladimir Vuksan, Christine C. Mehling, Giulio Testolin, Paul Corey, Stephen C. Cunnane, Marcella Garsetti
Rok vydání:	2002
Předmět:	Adult Dietary Fiber Male medicine.medical_specialty Health Status Population Medicine (miscellaneous) Blood Pressure Risk Assessment Gastroenterology Psyllium chemistry.chemical_compound Framingham Heart Study Risk Factors Internal medicine Humans Medicine education Drug Approval Glucans Completely randomized design Aged Aged 80 and over education.field_of_study Cross-Over Studies Nutrition and Dietetics Framingham Risk Score Dose-Response Relationship Drug business.industry Cholesterol Middle Aged Lipids Crossover study Apolipoproteins Endocrinology Blood pressure Solubility chemistry Cardiovascular Diseases Female business medicine.drug
Zdroj:	The American Journal of Clinical Nutrition. 75:834-839
ISSN:	0002-9165
DOI:	10.1093/ajcn/75.5.834
Popis:	BACKGROUND The US Food and Drug Administration (FDA) approved health claims for 2 dietary fibers, beta-glucan (0.75 g/serving) and psyllium (1.78 g/serving), on the assumption that 4 servings/d would reduce cardiovascular disease risk. OBJECTIVE We assessed the efficacy of this dose of fibers in reducing serum lipid risk factors for cardiovascular disease. DESIGN Sixty-eight hyperlipidemic adults consumed a test (high-fiber) and a control low-fat (25% of energy), low-cholesterol (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0509775f2488bb374f1a34554d97dedb https://doi.org/10.1093/ajcn/75.5.834 Zobrazit plný text záznamu